International expansion reinforces goBalto's leadership position
SAN FRANCISCO, August 30, 2016 -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today that CMIC HOLDINGS has chosen goBalto to further bolster CMIC HOLDINGS' clinical study startup process throughout Asia.
CMIC HOLDINGS is using goBalto's flagship product, Activate, for multi-country studies being conducted in Malaysia, Singapore, Taiwan, Philippines, Thailand, Japan, and South Korea. CMIC HOLDINGS is benefiting from Activate's robust library of country-specific workflows and management-based approach to site activation.
Activate allows CMIC HOLDINGS to track country and site milestones, streamlining the study startup process by ensuring clinical operations has real-time status updates, and ensuring efficiency gains by eliminating "hidden" communications created by relying on email and manual spreadsheets. CMIC HOLDINGS engages collaboratively with investigator sites using Activate to improve the communication process and to ultimately minimize the time to obtain critical documents.
Kazuo Nakamura, Chairman & CEO, at CMIC HOLDINGS stated, "Activate allows us to minimize risk in starting clinical trials and ensure compliance. Activate's workflows standardize processes and guide our clinical operations teams to complete and track specific documents and tasks for any site, country, or study based on regulatory requirements and our company's standard operating procedures (SOPs)."
"Activate allows the project management team at CMIC HOLDINGS to drive discussions and decision-making on bottlenecks impacting site activation. Significantly, time is not wasted charting data and compiling status updates, a practice that is typical with older methods, such as Excel," said Jae Chung, goBalto's founder and president. "The adoption of Activate at CMIC HOLDINGS further bolsters our international expansion and growth in the number of global clinical trials utilizing our industry first end-to-end study startup platform to accelerate clinical trials and speed therapies to patients in need."